But can pharma manufacturers do more to help prevent medication errors?

What impact will genetic changes have on new medicines currently in development?

It’s the timeless story: Teva wants Mylan, Mylan wants Perrigo, and Perrigo wants none of it

By eliminating protein A, researchers aim to deliver continuous processing at a fraction of the cost of conventional techniques.

Celebrating medicine makers of all stripes in our Top 100, we present The Medicine Maker Power List 2015!

We speak to Professor Begoña Calvo to find out more about her research into pharmaco vigilance for biosimilars.

What techniques will be in the toolbox 10 years from now? We speak to academic and industry experts to find out.

Phyllis Greenberger, President and CEO of the Society for Women’s Health Research (SWHR).

Glycan analysis poses major challenges for the biopharma industry; how can new technology lighten the load?

The potential for growth is huge, but how do you break into the market?